4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-3,6-dihydropyridine-(2H)-carboxamide derivatives as Limk and/or Rock kinases inhibitors for use in the treatment of cancer - Université d'Orléans Accéder directement au contenu
Brevet Année : 2021

4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-3,6-dihydropyridine-(2H)-carboxamide derivatives as Limk and/or Rock kinases inhibitors for use in the treatment of cancer

Hélène Bénédetti
Béatrice Vallée
Pascal Bonnet
Karen Plé
Samia Aci-Seche
Christian R. Andres
Patrick Vourc'H

Résumé

The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases.
Fichier non déposé

Dates et versions

hal-03555349 , version 1 (03-02-2022)

Identifiants

  • HAL Id : hal-03555349 , version 1

Citer

Sylvain Routier, Hélène Bénédetti, Béatrice Vallée, Pascal Bonnet, Karen Plé, et al.. 4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-3,6-dihydropyridine-(2H)-carboxamide derivatives as Limk and/or Rock kinases inhibitors for use in the treatment of cancer. France, Patent n° : WO2021239727 A1. BCT. 2021. ⟨hal-03555349⟩
87 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More